Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory TeamRenowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring
Glucotrack, Inc. Reminds Shareholders to VoteThe Special Meeting of Shareholders held on October 31, 2025
Glucotrack to Participate in the Q3 Virtual Investor SummitRUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025.
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, CardiologyExperienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual MeetingCompany to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study
Glucotrack Announces Repurchase of Series A WarrantsWarrant buyback extinguishes warrant liability accounting and share dilution overhang
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhDExperienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology DevelopmentPatients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic PancreasContinuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose MonitorNext Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board MemberLeading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
Glucotrack Announces Reverse Stock Split1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial OfficerIndustry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
Glucotrack Announces ISO 13485:2016 CertificationISO Certification highlights commitment to quality for continuous blood glucose monitor
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory AffairsNew hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
Glucotrack to Present at TechBio Showcase™ 2025Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAKINDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEMRutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
